MTMark Trinder

Mark Trinder

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mark Trinder has a total of 179 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Skin biopsy in adult-onset Still’s disease: A specific, rapid, and widely available diagnostic test

    by Derrick H.Y. Chong, Caroline Spaner, Ibrahim Elsharawi, Mark Trinder, Haya Al Bitar, Mariam Goubran, Amelia Perrotta, Rachael Horner, Dilys Chen, Jennifer Corpuz, et al.

    Adult-onset Still’s disease (AOSD) is a diagnostic challenge, as its features overlap with many inflammatory syndromes and no single finding is diagnostic. Skin biopsies showing dyskeratotic keratinocytes (DKs) in the superficial epidermis, including the horny layer, are thought to be highly specific for AOSD but are not included in current diagnostic or classification criteria. We conducted a retrospective clinicopathological study of 16 adults with confirmed AOSD and skin biopsies from a Canadian rare diseases program, and developed a differential diagnosis for superficial DKs using expert consensus and literature review. Clinical morphology varied, but histopathology was similar: 12 of 16 patients had DKs or necrotic keratinocytes in the upper epidermis. Superficial DKs have been reported in conditions distinct from AOSD, but not in its major mimics. Skin biopsy is low-cost, minimally invasive, and widely available and should be performed early in suspected AOSD; superficial DKs should be added to future diagnostic and classification criteria.

  • Castleman disease: application of modern classification in a Canadian center

    by Rebecca MacLeod, Mark Trinder, Liliana Wolak, Stephanie Quon, Marley Blommers, Mariam Goubran, Julia Varghese, Erica Peterson, Luke Y.C. Chen

    1. Castleman disease (CD) is a rare disease characterized by lymphadenopathy and a wide range of clinical manifestations ranging from focal lymphadenopathy to diffuse lymphoproliferation, systemic ...

  • Integration of a polygenic score into clinical risk prediction of atherosclerotic cardiovascular disease in familial hypercholesterolaemia

    by Martine Paquette, Mark Trinder, Isabelle Ruel, Simon-Pierre Guay, Robert A Hegele, Jacques Genest, Liam R Brunham, Alexis Baass

    Aims: A high polygenic risk score for coronary artery disease (PRSCAD) has been demonstrated to be a strong and independent predictor of atherosclerotic cardiovascular disease (ASCVD) in patients with familial hypercholesterolaemia (FH). The objective was to investigate if the addition of a PRSCAD to the FH-Risk-Score enhances ASCVD risk prediction compared with the clinical score alone. Methods and results: Data from three independent cohorts of patients with FH have been analysed in this longitudinal study (n = 1438). The FH-Risk-Score equation was used to calculate the baseline 10-year ASCVD risk. A high PRSCAD was defined as a score >75th percentile. The performance of the Combined score was assessed using measures of discrimination (C statistics), calibration (predicted risk vs. observed risk), and reclassification (using a 10-year risk cutoff of 20%). Overall, the event rate was nearly doubled in individuals having a high PRSCAD [15 vs. 9%, hazard ratio (HR) 1.77, 95% confidence interval (CI) 1.20–2.61, P = 0.004]. This association was stronger in those with a genetic confirmation of FH (17 vs. 8%, HR 2.34, 95% CI 1.50–3.67, P = 0.0002). The Combined score was associated with a marginally non-significant higher C-index than the FH-Risk-Score alone (0.746–0.750, P = 0.60). The difference in C-index was significant in patients with a genetic confirmation of FH in the moderate FH-Risk-Score group (0.617–0.717, P = 0.05). Conclusion: Overall, the addition of polygenic information using PRSCAD percentiles to the FH-Risk-Score estimate did not significantly enhance ASCVD risk prediction in patients with FH. Replication efforts with larger number of individuals and incident cases are warranted.

  • Open Access

    Lenalidomide‐Dexamethasone as an Effective and Well‐Tolerated Treatment Option for Refractory Rosai‐Dorfman‐Destombes Disease: A Clinical and Pharmacophenomic Study

    by Emily Leung, Nicholas R. Fragola, Elliott W. Sharp, Rebecca A. Harrison, Erica Peterson, Julia Varghese, Shannon Jackson, Xiaotian (Julie) You, Elysha VanderVeer, Mark Trinder, et al.

    A combined clinical and computational pharmacophenomic study from the Coastal Rare Inflammatory Diseases Program and Every Cure.


  • Open Access

    The Clinicopathologic Spectrum of Rosai–Dorfman–Destombes Disease in Adults: An Analysis of 16 Cases

    by Mark Trinder, Collin Pryma, Emily Leung, Graham W. Slack, Pedro Farinha, Sean Young, Neval Ozkaya, Mollie Carruthers, Luke Y. C. Chen

    Rosai–Dorfman–Destombes disease (RDD) is a rare histiocytic proliferation with protean clinical manifestations, resulting from the accumulation of activated histiocytes within nodal and extra‐nodal tissues. The diagnosis can be missed, particularly when biopsies are obtained from extra‐nodal sites, where histological features may be less specific than those observed in nodal specimens. Here, we examined a case series of 16 adults diagnosed with RDD from Vancouver, Canada between 2015 and 2025. Cases were classified as diagnostically challenging if the time to a definitive pathologic diagnosis exceeded 60 days from the initial biopsy for RDD‐related clinical symptoms and > 1 pathologic sampling was required to establish a diagnosis. Eight of 16 patients (50%) were classified as having diagnostically challenging cases. The median number of independent pathological samples required to establish a diagnosis of RDD was 2.0 (interquartile range: 2.3), with five patients needing three or more independent specimens. The median timeto final diagnosis was 12 days for non‐diagnostically challenging cases (IQR: 15 days) and 240 days for diagnostically challenging cases (IQR: 138 days). Notably, diagnostically challenging cases tended to have specimen sampling from atypical anatomical sites (62.5% vs. 37.5%), utilized suboptimal pathological sampling techniques (87.5% vs. 25.0%; e.g., cytology), and delayed or absent consultation with hematolymphoid‐specialized pathologists (25.0% vs. 87.5%). Together, this study underscores the extreme clinical heterogeneity of extra‐nodal RDD, emphasizes the critical role of expert hematolymphoid pathology expertise in its diagnosis, and suggests practical strategies—such as liberal use of immunohistochemistry on atypical histiocyte‐rich infiltrates—to avoid premature exclusion of RDD from the differential diagnosis.


  • Importance of Clinical, Laboratory, and Genetic Risk Factors for Incident CAD

    by Romit Bhattacharya, Christopher S. Marnell, So Mi Jemma Cho, Aniruddh P. Patel, Yunfeng Ruan, Satoshi Koyama, Amanda R. Jowell, Mark Trinder, Sara Haidermota, Kim Lannery, et al.

    BACKGROUND: Prior work suggests modifiable cardiovascular risk factors (CRFs) account for 80% to 90% of the risk for incident myocardial infarction. The contributions of genetic and other novel CRFs have not been simultaneously assessed in contemporary data sets. METHODS: In the United Kingdom Biobank, CRFs were identified and Cox proportional hazards models with traditional CRFs (hypertension, diabetes, dyslipidemia, waist-to-hip ratio, diet, exercise, alcohol, and socioeconomic deprivation) and contemporary/genetic CRFs (Lp(a) [lipoprotein(a)], hsCRP [high-sensitivity C-reactive protein], familial hypercholesterolemia variants, and polygenic risk score for coronary artery disease) were constructed for coronary artery disease. Coronary artery disease was defined as a first-time myocardial infarction diagnosis or coronary revascularization. R 2 was calculated for each model, and the percent contribution of each individual CRF was calculated by the R 2 percent decrease after its removal. RESULTS: Among 299 707 individuals, the mean (SD) age was 56.2 (8.1) years, and 166 533 (55.6%) were women. Over a median (interquartile range) follow-up of 11.0 (9.6–12.5) years, 17 409 (5.8%) of participants developed myocardial infarction. R 2 increased from the base model (R 2 , 0.021 [0.020–0.022]), to the clinical model (R 2 , 0.045 [0.043–0.046]), to the contemporary/genetic model (R 2 , 0.053 [0.052–0.055]). The most powerful individual CRFs were hypertension (R 2 loss, 15.2% [14.5–17.1]) and polygenic risk score for coronary artery disease (R 2 loss, 12.4% [10.8–13.3]), followed by dyslipidemia (R 2 loss, 3.4% [2.6–3.5]), diabetes (R 2 loss, 2.2% [1.5–2.0]), hsCRP (R 2 loss, 1.8% [1.5–2.0]), and Lp(a) (R 2 loss, 1.5% [1.2–1.8]). CONCLUSIONS: Novel CRFs like polygenic risk score for coronary artery disease, hsCRP, and Lp(a) have similar importance, comparable to traditional CRFs such as hypertension, dyslipidemia, and diabetes, for incident myocardial infarction, highlighting important identifiable residual risk factors.


  • Open Access

    High-density lipoprotein attenuates lipopolysaccharide-induced IL-1β activation via scavenger receptor class B type 1

    by Haoyu Deng, Wan Yi Liang, Leqi Chen, Kate Huang, Rylan Mccallum, Patrick C.N. Rensen, John H. Boyd, Mark Trinder, Liam R. Brunham


  • Predictors of Cardiovascular Disease in Individuals With Dysbetalipoproteinemia: A Prospective Study in the UK Biobank

    by Martine Paquette, Mark Trinder, Simon-Pierre Guay, Liam R Brunham, Alexis Baass

    Background Dysbetalipoproteinemia (DBL) is a disorder of remnant cholesterol metabolism associated with a severe risk of atherosclerotic cardiovascular disease (ASCVD). Objective The objective of this study was to investigate the univariate and multivariate predictors of ASCVD in individuals with DBL. Methods Data from 2,699 individuals with ε2/ε2 genotypes from the UK Biobank were included in this study. DBL was defined as having an ε2ε2 genotype with evidence of dyslipidemia, defined as total cholesterol ≥ 200 mg/dL [5.2 mmol/L] and TG ≥ 175 mg/dL [2.0 mmol/L]) or lipid-lowering therapy use (n=964). Results Age, hypertension, waist circumference and a polygenic risk score for coronary artery disease (PRSCAD) were independent predictors of ASCVD among individuals with DBL. Cumulative ASCVD-free survival was lower in the ε2/ε2 DBL group (84%) compared to the ε2/ε2 non-DBL group (94%) (pCAD ≥ median (79%) compared to those with a PRSCAD < median (89%) (p=0.001). Conclusion We show in a large prospective cohort that a PRSCAD predicts the ASCVD risk among individuals with DBL. The findings of the present study highlight the need for better risk stratification in ε2/ε2 carriers to identify high risk individuals that would need aggressive cardiovascular management despite their low apolipoprotein B value.


  • Genetic Architecture and Clinical Outcomes of Combined Lipid Disturbances

    by Thomas Gilliland, Jacqueline S. Dron, Margaret Sunitha Selvaraj, Mark Trinder, Kaavya Paruchuri, Sarah M. Urbut, Sara Haidermota, Rachel Bernardo, Mesbah Uddin, Michael C. Honigberg, et al.

    BACKGROUND: Dyslipoproteinemia often involves simultaneous derangements of multiple lipid traits. We aimed to evaluate the phenotypic and genetic characteristics of combined lipid disturbances in a general population-based cohort. METHODS: Among UK Biobank participants without prevalent coronary artery disease, we used blood lipid and apolipoprotein B concentrations to ascribe individuals into 1 of 6 reproducible and mutually exclusive dyslipoproteinemia subtypes. Incident coronary artery disease risk was estimated for each subtype using Cox proportional hazards models. Phenome-wide analyses and genome-wide association studies were performed for each subtype, followed by in silico causal gene prioritization and heritability analyses. Additionally, the prevalence of disruptive variants in causal genes for Mendelian lipid disorders was assessed using whole-exome sequence data. RESULTS: Among 450 636 UK Biobank participants: 63 (0.01%) had chylomicronemia; 40 005 (8.9%) had hypercholesterolemia; 94 785 (21.0%) had combined hyperlipidemia; 13 998 (3.1%) had remnant hypercholesterolemia; 110 389 (24.5%) had hypertriglyceridemia; and 49 (0.01%) had mixed hypertriglyceridemia and hypercholesterolemia. Over a median (interquartile range) follow-up of 11.1 (10.4–11.8) years, incident coronary artery disease risk varied across subtypes, with combined hyperlipidemia exhibiting the largest hazard (hazard ratio, 1.92 [95% CI, 1.84–2.01]; P =2×10 −16 ), even when accounting for non-HDL-C (hazard ratio, 1.45 [95% CI, 1.30–1.60]; P =2.6×10 −12 ). Genome-wide association studies revealed 250 loci significantly associated with dyslipoproteinemia subtypes, of which 72 (28.8%) were not detected in prior single lipid trait genome-wide association studies. Mendelian lipid variant carriers were rare (2.0%) among individuals with dyslipoproteinemia, but polygenic heritability was high, ranging from 23% for remnant hypercholesterolemia to 54% for combined hyperlipidemia. CONCLUSIONS: Simultaneous assessment of multiple lipid derangements revealed nuanced differences in coronary artery disease risk and genetic architectures across dyslipoproteinemia subtypes. These findings highlight the importance of looking beyond single lipid traits to better understand combined lipid and lipoprotein phenotypes and implications for disease risk.


  • Open Access

    Influence of Polygenic Background on the Clinical Presentation of Familial Hypercholesterolemia

    by Mark Trinder, Lubomira Cermakova, Isabelle Ruel, Alexis Baass, Martine Paquette, Jian Wang, Brooke A. Kennedy, Robert A. Hegele, Jacques Genest, Liam R. Brunham

    BACKGROUND: Heterozygous familial hypercholesterolemia (FH) is among the most common genetic conditions worldwide that affects ≈ 1 in 300 individuals. FH is characterized by increased levels of low-density lipoprotein cholesterol (LDL-C) and increased risk of coronary artery disease (CAD), but there is a wide spectrum of severity within the FH population. This variability in expression is incompletely explained by known risk factors. We hypothesized that genome-wide genetic influences, as represented by polygenic risk scores (PRSs) for cardiometabolic traits, would influence the phenotypic severity of FH. METHODS: We studied individuals with clinically diagnosed FH (n=1123) from the FH Canada National Registry, as well as individuals with genetically identified FH from the UK Biobank (n=723). For all individuals, we used genome-wide gene array data to calculate PRSs for CAD, LDL-C, lipoprotein(a), and other cardiometabolic traits. We compared the distribution of PRSs in individuals with clinically diagnosed FH, genetically diagnosed FH, and non-FH controls and examined the association of the PRSs with the risk of atherosclerotic cardiovascular disease. RESULTS: Individuals with clinically diagnosed FH had higher levels of LDL-C, and the incidence of atherosclerotic cardiovascular disease was higher in individuals with clinically diagnosed compared with genetically identified FH. Individuals with clinically diagnosed FH displayed enrichment for higher PRSs for CAD, LDL-C, and lipoprotein(a) but not for other cardiometabolic risk factors. The CAD PRS was associated with a risk of atherosclerotic cardiovascular disease among individuals with an FH-causing genetic variant. CONCLUSIONS: Genetic background, as expressed by genome-wide PRSs for CAD, LDL-C, and lipoprotein(a), influences the phenotypic severity of FH, expanding our understanding of the determinants that contribute to the variable expressivity of FH. A PRS for CAD may aid in risk prediction among individuals with FH.